In the News
Welcome to our news archive, your resource for company announcements, press releases, and media coverage. Here you’ll find updates on our latest initiatives, strategic partnerships, and industry contributions, as well as background materials to support media inquiries. Explore past stories to see how we continue to shape conversations across healthcare and life sciences.
A popular asthma medication, Xolair, was selected in the third cycle of the MDPNP—despite the fact that a competing biosimilar will launch before the negotiation period ends. Bloomberg Law taps MMIT’s Steve Callahan for his insights on the drug selection process and the biosimilar pipeline.
PharmaVoice tapped MMIT’s Madeline Verbeke and Evaluate’s Mark Lansdell for insights on market forces in 2026. Madeline addresses the obesity market’s expansion with the growth of oral and combination drugs, while Mark highlights expectations for high-value U.S. pharma / Chinese biotech deals in 2026.
This article from Drug Discovery & Development highlights the market’s strong M&A momentum and a surging Chinese deal landscape, featuring quotes from Evaluate’s Ben Folwell and Mark Lansdell. MMIT’s Madeline Verbeke shares her insights on obesity therapeutics, as new oral drugs are expected to capture meaningful market share.
For this article on GLP-1 market dynamics, Investor’s Business Daily reached out to MMIT CCO Jayne Hornung for her insights on pricing, affordability, and whether the oral version of these drugs will reach a previously untapped market.
For this investigative article about the origins, operations and impact of alternative funding programs (AFPs), Fierce Healthcare asked MMIT to provide a custom survey of payers and PBMs. Most are concerned about the legality of AFPs, an opinion shared by manufacturers, many of which prohibit patients with an AFP from applying to their patient support programs.
PharmaVoice reached out to MMIT’s Alicia Heesen for insights into how Merck’s release of the subcutaneous agent Keytruda Qlex will extend its market share and increase potential revenue. Alicia shares payer preferences for faster, less expensive, and more convenient treatment options.